Phase III Acute Coronary Syndrome
- Registration Number
- NCT00831441
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 7484
- Acute coronary syndrome (ACS)
- Clinically stable
- Receiving standard of care for ACS
- Severe hypertension
- Active bleeding or high risk for major bleeding
- Hemoglobin < 9 g/dL
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - Apixaban Apixaban -
- Primary Outcome Measures
Name Time Method Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days.
Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).
- Secondary Outcome Measures
Name Time Method Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3\*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5\*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice.
Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010).
Event Rate of Stroke During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination).
Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days.
Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).
Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days.
Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination.
Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years Cause of death was determined by the principal condition that caused the death, not the immediate mode of death.
CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination).Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days.
Trial Locations
- Locations (206)
Central Jersey Medical Research Center
🇺🇸Elizabeth, New Jersey, United States
Delmarva Heart Research Foundation
🇺🇸Salisbury, Maryland, United States
Washington University School Of Medicine
🇺🇸St. Louis, Missouri, United States
Carl Wilson Sofley, Jr., Md
🇺🇸Anderson, South Carolina, United States
Lowcountry Medical Group
🇺🇸Beaufort, South Carolina, United States
Parkway Cardiology Associates, Pc
🇺🇸Oak Ridge, Tennessee, United States
William Beaumont Hospital-Troy
🇺🇸Troy, Michigan, United States
Med Tech, Inc.
🇺🇸Houston, Texas, United States
Methodist Debakey Heart & Vascular Center
🇺🇸Houston, Texas, United States
Heart Center Research, Llc
🇺🇸Huntsville, Alabama, United States
Sparks Regional Medical Center
🇺🇸Fort Smith, Arkansas, United States
Nea Baptist Clinic
🇺🇸Jonesboro, Arkansas, United States
Phase Care, Llc
🇺🇸Alameda, California, United States
Cardiology Consultants Of Orange County
🇺🇸Anaheim, California, United States
Escondido Cardiology Associates, Inc.
🇺🇸Escondido, California, United States
Local Institution
🇬🇧New Castle Upon Tyne, Tyne And Wear, United Kingdom
William D. Bowden, D.O.
🇺🇸Healdsburg, California, United States
California Heart Specialists, Inc.
🇺🇸Huntington Beach, California, United States
Eisenstein, Isaac
🇺🇸Lakewood, California, United States
Caring Clinical Research Corporation
🇺🇸Laguna Hills, California, United States
Preciado Cardiology Incorporated
🇺🇸Los Angeles, California, United States
East Bay Physicians Medical Group
🇺🇸Oakland, California, United States
Arvind J. Mehta, Md
🇺🇸Long Beach, California, United States
St. Joseph Heritage Medical Group
🇺🇸Orange, California, United States
A.R.I. Clinical Trials, Inc.
🇺🇸Redondo Beach, California, United States
Harbbor-Ucla Medical Center
🇺🇸Torrance, California, United States
Coastal Multi-Specialty Research
🇺🇸Santa Ana, California, United States
Radiant Research, Inc
🇺🇸Santa Rosa, California, United States
Rocky Mountain Cardiology
🇺🇸Boulder, Colorado, United States
South Denver Cardiology Associates Pc
🇺🇸Littleton, Colorado, United States
Palm Beach Heart Institute, Llc
🇺🇸Atlantis, Florida, United States
Orlando Heart Specialists
🇺🇸Altamonte Springs, Florida, United States
Hartford Hospital
🇺🇸Hartford, Connecticut, United States
Drogue Medical, Llc
🇺🇸Wheat Ridge, Colorado, United States
Alfieri Cardiology
🇺🇸Newark, Delaware, United States
The Heart And Vascular Institute Of Florida
🇺🇸Clearwater, Florida, United States
Ronald L. Walsh, Do
🇺🇸Clearwater, Florida, United States
David E. Perloff, Md
🇺🇸Ft. Lauderdale, Florida, United States
Cardiovascular Specialist Of South Florida
🇺🇸Davie, Florida, United States
Nature Coast Clinical Research
🇺🇸Inverness, Florida, United States
Jacksonville Heart Center, Pa
🇺🇸Jacksonville, Florida, United States
Jacksonville Center For Clinical Research
🇺🇸Jacksonville, Florida, United States
East Coast Institute For Research
🇺🇸Jacksonville, Florida, United States
Alpha Medical Research, Llc
🇺🇸Melbourne, Florida, United States
The Cardio Vascular Center P.A.
🇺🇸Lake Mary, Florida, United States
Mount Sinai Medical Center
🇺🇸Miami Beach, Florida, United States
Mediquest Research Group Inc.
🇺🇸Ocala, Florida, United States
Melbourne Internal Medicine Associates (Mima)
🇺🇸Melbourne, Florida, United States
Ocala Research Institute, Inc
🇺🇸Ocala, Florida, United States
Palm Beach Gardens Research Center Llc
🇺🇸Palm Beach Gardens, Florida, United States
Cardiology Consultants
🇺🇸Pensacola, Florida, United States
Advent Clinical Research Centers, Inc.
🇺🇸Pinellas Park, Florida, United States
Cardio-Pulmonary Associates
🇺🇸Plantation, Florida, United States
Avivo Clin Clinical Services
🇺🇸Port Orange, Florida, United States
Heartcare Research
🇺🇸Sarasota, Florida, United States
St. Augustine Cardiology Associates
🇺🇸St. Augustine, Florida, United States
Howard T. Tee, M.D., F.A.C.P., F.A.C.C.
🇺🇸Vero Beach, Florida, United States
Indian River Cardiovascular Associates, Inc
🇺🇸Vero Beach, Florida, United States
Cardiology Partners Clinical Research Institute
🇺🇸Wellington, Florida, United States
Cardiovascular Physicians Of North Atlanta
🇺🇸Atlanta, Georgia, United States
Columbus Cardiology Associates Pc
🇺🇸Columbus, Georgia, United States
Medical College Of Georgia
🇺🇸Augusta, Georgia, United States
Georgia Heart Specialists
🇺🇸Covington, Georgia, United States
Atlanta Institute For Medical Research, Inc
🇺🇸Decatur, Georgia, United States
In-Quest Medical Research, Llc
🇺🇸Duluth, Georgia, United States
Alta Pharmaceutical Research Center, Inc.
🇺🇸Dunwoody, Georgia, United States
North Georgia Medical Research
🇺🇸Ellijay, Georgia, United States
Well Star Cardiovascular Medicine, Pc
🇺🇸Marietta, Georgia, United States
Mercer University School Of Medicine
🇺🇸Macon, Georgia, United States
Southern Heart Research Institute, Llc
🇺🇸Riverdale, Georgia, United States
Memorial Hospital Of Carbondale
🇺🇸Carbondale, Illinois, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
University Of Chicago Hospitals
🇺🇸Chicago, Illinois, United States
Clinical Investigation Specialists, Inc
🇺🇸Gurnee, Illinois, United States
Midwest Heart Foundation
🇺🇸Lombard, Illinois, United States
Illinois Heart & Lung Research
🇺🇸Normal, Illinois, United States
Heartcare Midwest
🇺🇸Peoria, Illinois, United States
Elkhart Clinic, Llc
🇺🇸Elkhart, Indiana, United States
St Margaret Mercy Healthcare Centers
🇺🇸Hammond, Indiana, United States
Medical Consultants, Pc
🇺🇸Muncie, Indiana, United States
Iowa Heart Center
🇺🇸West Des Moines, Iowa, United States
Mcfarland Clinic Pc
🇺🇸Ames, Iowa, United States
Kentucky Heart & Vascular Physicians
🇺🇸Ashland, Kentucky, United States
Research Integrity, Llc
🇺🇸Owensboro, Kentucky, United States
Alexandria Cardiology Clinic
🇺🇸Alexandria, Louisiana, United States
Clinical Research Network
🇺🇸Alexandria, Louisiana, United States
Louisiana State University Health Sciences Center-Shreveport
🇺🇸Shreveport, Louisiana, United States
Overton Brooks V.A.M.C.
🇺🇸Shreveport, Louisiana, United States
Louisiana Heart Center
🇺🇸Slidell, Louisiana, United States
Peninsula Cardiology Associates, P.A.
🇺🇸Salisbury, Maryland, United States
Thoracic And Cardiovascular Healthcare Foundation
🇺🇸Lansing, Michigan, United States
Endeavor Medical Research, Plc
🇺🇸Alpena, Michigan, United States
Genesys Regional Medical Center
🇺🇸Grand Blanc, Michigan, United States
Great Lakes Heart & Vascular Institute, Pc
🇺🇸St. Joseph, Michigan, United States
St Cloud Hospital
🇺🇸St. Cloud, Minnesota, United States
Bryanlgh Heart Institute
🇺🇸Lincoln, Nebraska, United States
University Of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
Gateway Cardiology, P.C.
🇺🇸St. Louis, Missouri, United States
Missouri Cardiovascular Specialists
🇺🇸Columbia, Missouri, United States
Hamilton Cardiology Associates
🇺🇸Hamilton, New Jersey, United States
The Valley Hospital
🇺🇸Ridgewood, New Jersey, United States
Central New Jersey Cardiology
🇺🇸South Plainfield, New Jersey, United States
Buffalo General Hospital
🇺🇸Buffalo, New York, United States
Dr. Michael Sacher
🇺🇸Massapequa, New York, United States
New York Methodist Hospital
🇺🇸Brooklyn, New York, United States
Hudson Valley Heart Center
🇺🇸Poughkeepsie, New York, United States
Asheville Cardiology Associates
🇺🇸Asheville, North Carolina, United States
Wake Med Heart Center
🇺🇸Raleigh, North Carolina, United States
Azalea Research Center
🇺🇸Wilmington, North Carolina, United States
East Carolina Heart Institute At East Carolina University
🇺🇸Greenville, North Carolina, United States
Wilmington Medical Research
🇺🇸Wilmington, North Carolina, United States
Otfried N. Niedermaier, Md
🇺🇸Akron, Ohio, United States
City Cardiology Associates
🇺🇸Barberton, Ohio, United States
Fairfield Cardiac Cath Lab, Llc
🇺🇸Fairfield, Ohio, United States
Genoa Medical Center
🇺🇸Genoa, Ohio, United States
Middletown Cardiovascular Associates
🇺🇸Middletown, Ohio, United States
Toledo Cardiology Consultants
🇺🇸Toledo, Ohio, United States
Cardiology Associates Of Southeastern Ohio
🇺🇸Zanesville, Ohio, United States
Blue Stem Cardiology
🇺🇸Bartlesville, Oklahoma, United States
St. Charles Health System, Inc.
🇺🇸Bend, Oregon, United States
St. Lukes Cardiology Associates
🇺🇸Bethlehem, Pennsylvania, United States
Consultants In Cardiovascular Diseases, Inc.
🇺🇸Erie, Pennsylvania, United States
Hamot Medical Center
🇺🇸Erie, Pennsylvania, United States
Richard M. Kastelic M.D. & Associates, P.C.
🇺🇸Johnstown, Pennsylvania, United States
The Heart Group
🇺🇸Lancaster, Pennsylvania, United States
Drexel University College Of Medicine
🇺🇸Philadelphia, Pennsylvania, United States
Penn Presbyterian Medical Center
🇺🇸Philadelphia, Pennsylvania, United States
Pennsylvania Cardiology Associates
🇺🇸Philadelphia, Pennsylvania, United States
Va Pittsburgh Healthcare System
🇺🇸Pittsburgh, Pennsylvania, United States
Pottstown Medical Specialists, Inc
🇺🇸Pottstown, Pennsylvania, United States
Buxmont Cardiology Associates, Pc
🇺🇸Sellersville, Pennsylvania, United States
The Miriam Hospital
🇺🇸Providence, Rhode Island, United States
Moffit Heart & Vascular Group
🇺🇸Wormleysburg, Pennsylvania, United States
Anmed Health
🇺🇸Anderson, South Carolina, United States
Cardiology Assoicates, Pc/Black Hills Clinical Research Ctr
🇺🇸Rapid City, South Dakota, United States
Columbia Cardiology
🇺🇸Columbia, South Carolina, United States
North Central Heart Institute
🇺🇸Sioux Falls, South Dakota, United States
The Chattanooga Heart Institute
🇺🇸Chattanooga, Tennessee, United States
The Stern Cardiovascular Center, Pa
🇺🇸Germantown, Tennessee, United States
Research Associates Of Jackson
🇺🇸Jackson, Tennessee, United States
Knoxville Heart Group
🇺🇸Knoxville, Tennessee, United States
Mountain State Health Alliance
🇺🇸Johnson City, Tennessee, United States
Amarillo Heart Clinical Research Institute Inc.
🇺🇸Amarillo, Texas, United States
Dallas Va Medical Center
🇺🇸Dallas, Texas, United States
Cardiovascular Research Institute Of Dallas
🇺🇸Dallas, Texas, United States
Heart Consultants Of North Texas
🇺🇸Dallas, Texas, United States
Texas Health Research & Education Institute
🇺🇸Fort Worth, Texas, United States
T&R Clinic
🇺🇸Fort Worth, Texas, United States
Heart Care Center
🇺🇸Houston, Texas, United States
Centex Research, Pineloch Medical Clinic
🇺🇸Houston, Texas, United States
Northwest Houston Cardiology, Pa
🇺🇸Houston, Texas, United States
Texas Cardiac Center
🇺🇸Lubbock, Texas, United States
Northwest Heart Center
🇺🇸Tomball, Texas, United States
Scott&White Memorial Hospital
🇺🇸Temple, Texas, United States
Sugarland Cardiology Associates
🇺🇸Sugarland, Texas, United States
Tyler Cardiovascular Consultants
🇺🇸Tyler, Texas, United States
Bermisa Family Practice & Research Center
🇺🇸Chesapeake, Virginia, United States
Utah Cardiology P.C
🇺🇸Layton, Utah, United States
Zakhary, Bosh
🇺🇸Danville, Virginia, United States
Heart Care Associates P.C.
🇺🇸Hopewell, Virginia, United States
The Cardiology Group Centra.
🇺🇸Lynchburg, Virginia, United States
Sendara Cardiovasular Research Institute
🇺🇸Norfolk, Virginia, United States
Virginia Cardiolovascular Associates
🇺🇸Manassas, Virginia, United States
Inland Cardiology Associates
🇺🇸Spokane, Washington, United States
Franciscan Research Center
🇺🇸Tacoma, Washington, United States
Glenn J. Barquet, Md
🇺🇸Miami, Florida, United States
Advanced Pharma Clinical Research
🇺🇸Miami, Florida, United States
Krannertt Institute Of Cardiology
🇺🇸Indianapolis, Indiana, United States
Miami Cardiology Clinical Research, L.L.C.
🇺🇸Miami, Florida, United States
R. L.Roudebush Va Medical Center
🇺🇸Indianapolis, Indiana, United States
The Care Group, Llc
🇺🇸Indianapolis, Indiana, United States
Cincinnati Veterans Affairs Medical Center
🇺🇸Cincinnati, Ohio, United States
Hennepin County Medical Center
🇺🇸Minneapolis, Minnesota, United States
Va Medical Center
🇺🇸Minneapolis, Minnesota, United States
University Of Minnesota, Medical School
🇺🇸Minneapolis, Minnesota, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Central Cardiovascular Institute Of San Antonio
🇺🇸San Antonio, Texas, United States
Jose A. Perez, M.D.
🇺🇸San Antonio, Texas, United States
S.A.M. Clinical Research Center
🇺🇸San Antonio, Texas, United States
Midwest Cardiology Associates , P.C.
🇺🇸Overland Park, Kansas, United States
North Phoenix Heart Center
🇺🇸Phoenix, Arizona, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Cor Clinical Research, Llc
🇺🇸Oklahoma City, Oklahoma, United States
University Of Oklahoma Health Sciences Center
🇺🇸Oklahoma City, Oklahoma, United States
Oklahoma Cardiovascular Associates
🇺🇸Oklahoma City, Oklahoma, United States
Access Clinical Trials
🇺🇸Nashville, Tennessee, United States
Uab Medical Center
🇺🇸Birmingham, Alabama, United States
University Of Alabama At Birmingham
🇺🇸Birmingham, Alabama, United States
Heart Consultants
🇺🇸Omaha, Nebraska, United States
Alegent Health Clinic Heart & Vascular Specialists
🇺🇸Omaha, Nebraska, United States
Portland Preventive Cardiology, L.L.C.
🇺🇸Portland, Oregon, United States
Wheaton Franciscan Healthcare St. Joseph
🇺🇸Milwaukee, Wisconsin, United States
Dr Kiran C Patel Research Institute At Pepin Heart Hospital
🇺🇸Tampa, Florida, United States
Covenant Medical Center, Inc
🇺🇸Saginaw, Michigan, United States
Florida Heart Group
🇺🇸Orlando, Florida, United States
Orlando Heart Center
🇺🇸Orlando, Florida, United States
Cardiovascular Associates, Psc
🇺🇸Louisville, Kentucky, United States
The University Of North Carolina At Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Tulane University Hospital And Clinic
🇺🇸New Orleans, Louisiana, United States
Virgina Commonwealth Universitymedical Center
🇺🇸Richmond, Virginia, United States
Dean And St. Mary'S Outpatient Center
🇺🇸Madison, Wisconsin, United States
Blair Medical Associates, Inc.
🇺🇸Altoona, Pennsylvania, United States
Northeast Georgia Heart Cntr, Pc
🇺🇸Gainesville, Georgia, United States
Beaver Medical Group
🇺🇸Banning, California, United States
Gateway Cardiology. P.C
🇺🇸Jerseyville, Illinois, United States